Phase 1 trial of intrathecal azacitidine and nivolumab in patients with recurrent high-grade glioma
This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.